Research and Clinical Trials on Venlafaxine (Effexor, Efexor)

Venlafaxine (Effexor, Efexor) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Venlafaxine (Effexor, Efexor).

• A Study of Eszopiclone Co-Administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
  Status: Recruiting, Condition Summary: Major Depressive Disorder; Insomnia
• Aripiprazole and Effexor XR Drug Interaction Study
  Status: Completed, Condition Summary: Healthy
• Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
  Status: Recruiting, Condition Summary: Breast Cancer; Depression; Hot Flashes; Psychosocial Effects/Treatment
• Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer
  Status: Recruiting, Condition Summary: Hot Flashes; Prostate Cancer
• A Safety, Efficacy and Tolerability Study of SEP-225289
  Status: Recruiting, Condition Summary: Depressive Disorder, Major
• Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals
  Status: Active, not recruiting, Condition Summary: Cocaine-Related Disorders
• Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
  Status: Recruiting, Condition Summary: Depression; Marijuana Abuse
• Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
  Status: Recruiting, Condition Summary: Breast Cancer; Hot Flashes; Sleep Disorders
• Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
  Status: Completed, Condition Summary: Hot Flashes
• Comparison of the Pharmacokinetic of Two Generic Antidepressants and Their Respective Brand Preparations
  Status: Recruiting, Condition Summary: Therapeutic Equivalency; Human Experimentation
• Venlafaxine Augmentation in Treatment Resistant Depression
  Status: Recruiting, Condition Summary: Depression
• A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
  Status: Completed, Condition Summary: Depressive Disorder, Major
• Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury
  Status: Active, not recruiting, Condition Summary: Neuropathic Pain; Pain; Spinal Cord Injuries
• Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
  Status: Completed, Condition Summary: Anxiety
• Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
  Status: Recruiting, Condition Summary: Social Phobia

 

Get These Clinical Trials as a Newsfeed

Venlafaxine:             

Current Research Literature on Venlafaxine (Effexor, Efexor)

Here are abstracts for some of the latest research articles to have appeared on Venlafaxine (Effexor, Efexor):

Sustained-release pellets prepared by combination of wax matrices and double-layer coatings for extremely water-soluble drugs.

Drug Dev Ind Pharm. 2008 Jun; 34(6): 569-76
Tian L, Zhang Y, Tang X
This study was performed in order to develop a sustained-release pellet formulation containing venlafaxine hydrochloride (VEN), an extremely water-soluble drug, prepared by combination of wax matrices and double-layer coatings. The influence of both double-layer polymeric coats and wax matrices on the release of VEN from sustained-release pellets was investigated. The pellets were prepared by wet mass extrusion spheronization methods and then coated with a fluidized bed coater. For the pellets coated with Eudragit NE30D alone, a coating level of nearly 40% was required to pass the dissolution test compared with commercial product, and it was accompanied by an unacceptable lag time. The application of an alcohol-soluble polymeric subcoat, Opadry I, was added before the Eudragit NE30D coating process, which resulted in a marked delay in drug release. However, a faster release was observed for the formulation coated with a high subcoat level (10%) at the end of the dissolution test. A further delay in drug release was observed when a wax matrix, octadecanol, was added to the core pellet formulation. The kinetics of drug release changed from the Higuchi model to a zero order model and the predominant mechanism controlling drug release changed from diffusion to dissolution upon increasing the amount of octadecanol within the matrix pellets. In addition, the drug release was markedly influenced by the drug to matrix ratio. In conclusion, the 40% drug-loaded core pellets with double-layer coatings (8% Opadry I and 12% Eudragit NE30D) and 20% octadecanol matrix produced the desired profile for once-daily sustained release compared with the commercial product, and these pellets remained stable during storage.

Duloxetine-induced hypomania: case report and brief review of the literature on SNRIs-induced mood switching.

J Psychopharmacol. 2008 Jun 18;
Peritogiannis V, Antoniou K, Mouka V, Mavreas V, Hyphantis TN
Abstract Manic switching during antidepressant treatment has been reported with every class of antidepressant drugs. Serotonin-noradrenaline reuptake inhibitors (SNRIs) have been increasingly used for the treatment of unipolar and bipolar depression and are well tolerated and sufficiently effective because of their dual mechanism of action. A case of duloxetine-induced hypomania in a non-bipolar patient is presented, and a brief review of all the cases of SNRIs' induced mania and hypomania has been carried out. The available data suggest that SNRIs, especially venlafaxine, can induce mood switching in patients with bipolar depression and in certain patients with unipolar depression, but the potential of duloxetine and milnacipran to induce manic or hypomanic symptoms cannot be disregarded. Switching appears to be dose related and treatment initiation with lower doses and upward titration when needed may be preferable in selected cases and may help minimizing the risk of mood switching.

High-dose venlafaxine in delusional and severely depressed patients.

J Psychopharmacol. 2008 Jun 18;
Ruiz-Doblado S, Rueda-Villar T, Casillas-Lara L

Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.

J Psychopharmacol. 2008 Jun 18;
van den Broek WW, Mulder PG, van Os E, Birkenhäger TK, Pluijms E, Bruijn JA
Abstract With respect to the pharmacological characteristic, venlafaxine is comparable with tricyclic antidepressants (TCAs), and venlafaxine might be comparable in efficacy. We performed a systematic review investigating the relative efficacy and tolerability of venlafaxine compared with TCAs (imipramine, clomipramine, amitriptyline, nortriptyline and desipramine). Relevant double-blind randomised trials were identified from systematic searches of electronic databases. An exact analysis of the estimated odds ratios of response of the TCA relative to venlafaxine showed no overall significance of treatment effect (P = 0.38). The odds ratios were not homogenous across studies (P = 0.0213). The average dose of venlafaxine was 103.5 mg/day and for the TCA 106.1 mg/day. An exact analysis of the estimated odds ratios of the withdrawals and side effects in the trials with a TCA relative to venlafaxine showed no overall significance of withdrawal. From our review, no significant difference in treatment effect between low dose of both venlafaxine and the TCAs could be found. In our opinion, because of the heterogeneity of the odds ratios, one cannot conclude that they are of equal efficacy.

[In Process Citation]

Encephale. 2008 Jun; 34(3): 280-3
Millet B
Escitalopram has shown some different pharmacologic properties compared to its racemic molecule, citalopram. When comparing with venlafaxine, similar efficacy of this drug was observed, notably when considering the frequency of responders [50% of decrease on the Montgomery and Asberg Depression rating Scale (MADRS)] and the frequency of remitters (MADRS